Capital Counsel’s AbbVie ABBV Stock Holding History

Capital Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+801	New	+$172K	0.01%	56
2016 Q1	–	Sell	-7,596	Closed	-$450K	–	62
2015 Q4	$450K	Buy	7,596 +2,500	+49%	+$144K	0.02%	78
2015 Q3	$277K	Sell	5,096 -7,000	-58%	-$456K	0.01%	100
2015 Q2	$813K	Hold	12,096	–	–	0.04%	63
2015 Q1	$708K	Buy	12,096 +671	+6%	+$40.5K	0.03%	72
2014 Q4	$748K	Hold	11,425	–	–	0.04%	69
2014 Q3	$660K	Hold	11,425	–	–	0.04%	68
2014 Q2	$645K	Hold	11,425	–	–	0.04%	69
2014 Q1	$587K	Hold	11,425	–	–	0.03%	76
2013 Q4	$603K	Buy	11,425 +75	+0.7%	+$3.69K	0.03%	76
2013 Q3	$508K	Hold	11,350	–	–	0.03%	74
2013 Q2	$469K	Buy	+11,350	New	+$496K	0.03%	76

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Counsel's ABBV Position: Q2 2026 in Review

Capital Counsel opened a new position in AbbVie (ABBV) in Q2 2026: 801 shares worth $202K. The stake represents 0.01% of the portfolio and ranks #56 among its holdings. This is a return to the name: Capital Counsel previously reported a position in ABBV as recently as Q4 2015.

Capital Counsel first reported a position in ABBV in Q2 2013 and has held it in 12 quarters since. The position peaked at $813K in Q2 2015. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capital Counsel held 801 shares of AbbVie worth $202K as of Q2 2026.
AbbVie was a new Capital Counsel position in Q2 2026.
AbbVie made up 0.01% of Capital Counsel's portfolio in Q2 2026, its #56 holding.
Capital Counsel first reported a position in AbbVie in Q2 2013 and has held it in 12 quarters since.
Capital Counsel's AbbVie position peaked at $813K in Q2 2015.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.